The CYP17 MspA1 polymorphism is not associated with an increased risk of uterine leiomyomas in a Japanese population

References

• Otubu J A, Buttram V C, Besch N F, Besch P K. Unconjugated steroids in leiomyomas and tumor-bearing myometrium. Am J Obstet Gynecol 1982; 143: 130–133
   PubMedGoogle Scholar
• Pasqualini J R, Cornier E, Grenier J, Vella C, Schatz B, Netter A. Effect of decapeptyl, an agonistic analog of gonadotropin-releasing hormone on estrogens, estrogen sulfates, and progesterone receptors in leiomyoma and myometrium. Fertil Steril 1990; 53: 1012–1017
   Google Scholar
• Sumitani H, Shozu M, Segawa T, Murakami K, Yang H J, Shimada K, Inoue M. In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism. Endocrinology 2000; 141: 3852–3861
   PubMed Web of Science ®Google Scholar
• Benassayag C, Leroy M J, Rigourd V, Robert B, Honore J C, Mignot T M, Vacher-Lavenu M C, Chapron C, Ferre F. Estrogen receptors (ERα/ERβ) in normal and pathological growth of the human myometrium: pregnancy and leiomyoma. Am J Physiol Endocrinol Metab 1999; 276: E1112–E1118
   PubMed Web of Science ®Google Scholar
• Kovács K A, Oszter A, Göcze P M, Környei J L, Szabó I. Comparative analysis of cyclin D1 and oestrogen receptor (α and β) levels in human leiomyoma and adjacent myometrium. Mol Hum Reprod 2001; 7: 1085–1091
   PubMed Web of Science ®Google Scholar
• Weel A E, Uitterlinden A G, Westendorp I C, Burger H, Schuit S C, Hofman A, Helmerhorst T J, van Leeuwen J P, Pols H A. Estrogen receptor polymorphism predicts the onset of natural and surgical menopause. J Clin Endocrinol Metab 1999; 84: 3146–3150
   PubMed Web of Science ®Google Scholar
• Kitawaki J, Obayashi H, Ishihara H, Koshiba H, Kusuki I, Kado N, Tsukamoto K, Hasegawa G, Nakamura N, Honjo H. Oestrogen receptor-α gene polymorphism is associated with endometriosis, adenomyosis and leiomyomata. Hum Reprod 2001; 16: 51–55
   PubMed Web of Science ®Google Scholar
• Massart F, Becherini L, Gennari L, Facchini V, Genazzani A R, Brandi M L. Genotype distribution of estrogen receptor-α gene polymorphisms in Italian women with surgical uterine leiomyomas. Fertil Steril 2001; 75: 567–570
   PubMed Web of Science ®Google Scholar
• Hsieh Y Y, Chang C C, Tsai F J, Tsai H D, Yeh L S, Lin C C, Tsai C H. Estrogen receptor thymine–adenine dinucleotide repeat polymorphism is associated with susceptibility to leiomyoma. Fertil Steril 2003; 79: 96–99
   PubMed Web of Science ®Google Scholar
• Zuber M X, Simpson E R, Waterman M R. Expression of bovine 17α-hydroxylase cytochrome P-450 cDNA in nonsteroidogenic (COS 1) cells. Science 1986; 234: 1258–1261
   PubMed Web of Science ®Google Scholar
• Picado-Leonard J, Miller W L. Cloning and sequence of the human gene for P450c17 (steroid 17α-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA 1987; 6: 439–448
   PubMedGoogle Scholar
• Carey A H, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994; 3: 1873–1876
   PubMed Web of Science ®Google Scholar
• Kristensen V N, Haraldsen E K, Anderson K B, Lonning P E, Erikstein B, Karesen R, Gabrielsen O S, Borresen-Dale A L. CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res 1999; 59: 2825–2828
   PubMed Web of Science ®Google Scholar
• Huang C -S, Chern H -D, Chang K -J, Cheng C -W, Hsu S -M, Shen C -Y. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 1999; 59: 4870–4875
   PubMed Web of Science ®Google Scholar
• Feigelson H S, McKean-Cowdin R, Coetzee G A, Stram D O, Kolonel L N, Henderson B E. Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res 2001; 61: 785–789
   PubMed Web of Science ®Google Scholar
• Haiman C A, Hankinson S E, Colditz G A, Hunter D J, de Vivo I. A polymorphism in CYP17 and endometrial cancer risk. Cancer Res 2001; 61: 3955–3960
   PubMed Web of Science ®Google Scholar
• Yamada Y, Watanabe M, Murata M, Yamanaka M, Kubota Y, Ito H, Katoh T, Kawamura J, Yatani R, Shiraishi T. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5α-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int J Cancer 2001; 92: 683–686
   PubMed Web of Science ®Google Scholar
• Kittles R A, Panguluri R K, Chen W, Massac A, Ahaghotu C, Jackson A, Ukoli F, Adams-Campbell L, Isaacs W, Dunston G M. CYP17 promoter variant associated with prostate cancer aggressiveness in African Americans. Cancer Epidemiol Biomarkers Prev 2001; 10: 943–947
   Google Scholar
• Stanford J L, Noonan E A, Iwasaki L, Kolb S, Chadwick R B, Feng Z, Ostrander E A. A polymorphism in the CYP17 gene and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002; 11: 243–247
   PubMedGoogle Scholar
• Garner E IO, Stokes E E, Berkowitz R S, Mok S C, Cramer D W. Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer. Cancer Res 2002; 62: 3058–3062
   PubMed Web of Science ®Google Scholar
• Feigelson H S, Shames L S, Pike M C, Coetzee G A, Stanczyk F Z, Henderson B E. Cytchrome P450c17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998; 58: 585–587
   PubMed Web of Science ®Google Scholar
• Ambrosone C B, Moysich K B, Furberg H, Freudenheim J L, Bowman E D, Ahmed S, Graham S, Vena J E, Shields P G. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors. Breast Cancer Res 2003; 5: R45–R51
   PubMed Web of Science ®Google Scholar
• Wu A H, Seow A, Arakawa K, Van Berg den D, Lee H -P, Yu M C. HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore. Int J Cancer 2003; 104: 450–457
   PubMed Web of Science ®Google Scholar
• Ntais C, Polycarpou A, Ioannidis J PA. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003; 12: 120–126
   PubMed Web of Science ®Google Scholar
• Spurdle A B, Chen X, Abbazadegan M, Martin N, Khoo S K, Hurst T, Ward B, Webb P M, Chenevix-Trench G. CYP17 promoter polymorphism and ovarian cancer risk. Int J Cancer 2000; 86: 436–439
   Google Scholar
• Goodman M T, McDuffie K, Guo C, Terada K, Donlon T A. CYP17 genotype and ovarian cancer: a null case–control study. Cancer Epidemiol Biomarkers Prev 2001; 10: 563–564
   Google Scholar
• Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S. Genetic polymorphism in CYP17 and breast cancer risk in Japanese women. Eur J Cancer 2000; 36: 2375–2379
   PubMedGoogle Scholar
• Kado N, Kitawaki J, Obayashi H, Ishihara H, Koshiba H, Kusuki I, Tsukamoto K, Hasegawa G, Nakamura N, Yoshikawa T, Honjo H. Association of the CYP17 gene and CYP19 gene polymorphisms with risk of endometriosis in Japanese women. Hum Reprod 2002; 17: 897–902
   PubMed Web of Science ®Google Scholar
• Fujimoto J, Hirose R, Sakaguchi H, Tamaya T. Expression of size-polymorphic androgen receptor gene in uterine leiomyoma according to the number of cytosine, adenine, and guanine repeats in androgen receptor alleles. Tumour Biol 2000; 21: 33–37
   PubMedGoogle Scholar
• Hashimoto K, Azuma C, Kamiura S, Koyama M, Nobunaga T, Tokugawa Y, Kimura T, Kubota Y, Sawai K, Saji F. Maintenance of imprinting of the insulin-like growth factor II gene (IGF2) and the small nuclear ribonucleoprotein polypeptide N gene (SNRPN) in the human uterus and leiomyoma. Gynecol Obstet Invest 1996; 41: 50–54
   PubMedGoogle Scholar
• Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S. Breast cancer risk associated with polymorphism in CYP19 in Japanese women. Int J Cancer 2000; 89: 325–328
   Google Scholar
• Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma V M, Benhamou S, Kang D, Vainio H, Uusitupa M, Hirvonen A. Polymorphic catechol-O-methyltranferase gene and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10: 635–640
   PubMed Web of Science ®Google Scholar